The various studies in this thesis focused around one of three major themes, including;
1.
Personalizing treatment-strategies ■ What did we learn from recently published studies on calprotectin monitoring in patients on induction therapy? ■ Can we predict what type of patients should be treated with anti-TNF agents early in the course of their disease? ■ What is the "Dutch experience" with Methotrexate maintenance therapy in children with Crohn's disease?
2.
Optimizing accuracy of fecal calprotectin measurements in disease monitoring ■ Is the use of sent-in stool samples really the way to go? ■ Should we advise all patients with IBD to analyze their own stool at home?
3.
Profiling patients with childhood-onset sclerosing cholangitis ■ What did we learn from comparing a cohort of patients with childhood-onset primary sclersoing cholangitis with a cohort with adult-onset primary sclerosing cholangitis? ■ Can the identification of disease-causing rare genetic variants in patients with early-onset primary sclerosing cholangitis lead to patientspecific therapies?
In the following chapter the main results are summarized, and clinical implications of the findings are discussed. Furthermore, a sketch of tomorrow's IBD care is drawn. 201 9 In chapter 2, we systematically searched the literature on the value of calprotectin monitoring in IBD patients on induction therapy. We identified four studies, including only adult patients, that qualified for inclusion in the meta-analysis. This limited number of suitable trials is indicative of the relatively new application of stool calprotectin to monitor disease activity. Based on the results of our meta-analysis we concluded that performing measurements at the start of induction therapy and at the end is useful to determine if the patient is responding adequately to the treatment or whether further treatment intensification is warranted. We suggest that, rather than merely a decline in stool calprotectin concentration, a pre-specified calprotectin target range needs to be reached which corresponds with disease in endoscopic remission, or mucosal healing, to be able to say that the treatment was truly successful.
In chapter 3, we evaluated whether calprotectin-based disease monitoring is helpful in determining the response to treatment in paediatric practice. We prospectively followed a cohort of children with newly-onset IBD during their first year after diagnosis and tested whether time-to-reach target calprotectin predicted sustained remission. We observed that a larger proportion of children with ulcerative colitis (UC) compared to Crohn's disease (CD) reached the calprotectin target range, and at an earlier time point after starting induction therapy. The state of remission in UC patients lasted shorter than in CD patients. Reaching the target within 12 weeks predicted sustained remission in CD, but not in UC. This finding suggests that a quick response to conventional induction therapy, based on calprotectin values in the target range, allows to identify those with a favourable disease course. Patients who do not have a quick response may need accelerated step-up to anti-TNF agents.
In chapter 4 we reported about the efficacy and tolerability of methotrexate (MTX) immunomodulation after thiopurine failure or intolerance. We showed that MTX is a good alternative for maintenance treatment in paediatric CD patients, especially for those who are thiopurine intolerant, before deciding to step up to anti-TNF therapy.
Clinical Implications
Over the last decade, we have seen advances in biological therapies -new drugs intervening with inflammatory responses, such as vedolizumab and ustekinumab -and small molecule therapies (tofacitinib) that target specific steps in the inflammatory pathways. (1) (2) (3) (4) However, none of these drugs can be considered as precision drugs that take into account individual variability in genes, environment and lifestyle for each person. Although current therapeutics aim at countering the immune response, they are rather unrefined and therefore impact adversely on the rest of the body and increase the risk for infections and malignancy. (5, 6) Both researchers and clinicians therefore aim to expose only those patients that are really in need of these new drugs, balancing the risk of ongoing inflammation leading to irreversible bowel damage and the need of surgery versus the risk of adverse events. The initiative described in chapter 3, to identify at an early stage those patients that require an accelerated step-up to anti-TNF is, in fact, nothing more than treating bad diseases at diagnosis in a more aggressive manner.
Many of the new drugs have shown to induce mucosal healing (MH), a state that describes the absence of both endoscopic and histologic inflammation, which has recently become the main treatment target in IBD. Reaching and maintaining MH is thought to stop disease progression in the long term. Increasingly researchers and clinicians put confidence in the motto "the first blow is half the battle" and promote the early institution of biologic therapy. (7) (8) (9) (10) (11) (12) The short-term results of early intensive treatment are promising. Nevertheless, it is difficult to fully justify the start of such a new treatment strategy. Proper monitoring of the effects in a research setting is therefore crucial to keep moving forward. With the treat-to-target strategy, the response to treatment should be closely followed by using objective clinical and biological outcome measures. If there is a lack of response, initial treatment should be escalated. The CALM study published in 2017, investigated the effectiveness and safety of two treatment algorithms (clinical symptoms combined with biomarkers versus clinical symptoms alone) in achieving MH in CD patients. (13) This was the first treat-to-target trial in IBD, that also tested faecal calprotectin (FC) as a treatment target, with levels below 250 μg/g considered to indicate a satisfactory therapeutic response to treatment and treatment escalation with anti-TNF therapy when FC was ≥ 250 μg/g. The FC-based 203 9 strategy appeared to result in better clinical and endoscopic outcomes than symptom-driven decisions alone. The CALM study also indicated that choosing an appropriate FC target level was a critical element of FC-based monitoring. Choosing a target which is too low (e.g. 100 µg/g), may lead to a smaller percentage of false negative cases and will prevent undertreatment. However, this might also cause physicians to switch the treatment faster and therefore use the available arsenal of therapeutics at an increased rate. There is no consensus about the optimal FC target range yet and the question remains whether it is appropriate to pursue one action threshold for all patients or if a patient should have a personal action threshold. (14) (15) (16) (17) (18) This is because the calprotectin-concentration is not only dependent on the extent and severity of the inflammation, but also on the contact time between stool and inflamed tissue. The location of the inflamed area in the gastrointestinal tract and the intestinal transit rate are therefore important factors which (co-)influence the calprotectin concentration.
Since we are just at the start of the treat-to-target strategy, we do not yet know its long-term effects. Does this strategy really prevent disease progression and irreversible intestinal fibrosis? Do fewer patients need to undergo surgical interventions? During the 2019 European Crohn's and Colitis Organisation (ECCO) congress in Copenhagen it was reported that the early CD patients, of the previously mentioned CALM study, who achieved endoscopic or deep remission after 1 year of intensive treatment were less likely to have disease progression over a median of 3 years. (19) These first long(er)-term results of the treat-to-target strategy are expected to be published this year.
In 1971, thiopurine therapy was introduced as a useful treatment option for CD and the long-term effects were unknown as well. (20) For a long time the thiopurines have been used as the immunomodulators of choice for moderate to severe UC and CD. The increased use of anti-TNF agents in IBD led to a reappraisal of the role of immunomodulators in the treatment, since combination therapy of thiopurines and anti-TNF medication has been shown to be more effective and to reduce the risk of development of anti-drug antibodies. (20) (21) (22) However, some studies have reported an association between the use of thiopurines and an increased risk of developing lymphomas. (23) This is why, in paediatric practice, thiopurines are nowadays prescribed with 204 9 reservation. This has also resulted in a renewed interest in the use of methotrexate (MTX) immunomodulation. (24) (25) (26) (27) (28) (29) (30) (31) In chapter 4 we showed that it is worthwhile to consider MTX as a secondline immunomodulator, especially in those who are thiopurine intolerant, before stepping up to anti-TNF therapy. More studies are needed to assess the long-term efficacy and safety of MTX in the treatment of CD patients to determine whether MTX might be used as primary immunomodulator instead of thiopurine.
In IBD, there is only one study available discussing the use of MTX in combination with anti-TNF therapy, concluding that the combination of infliximab and methotrexate, although safe, was no more effective than infliximab alone in patients with CD receiving treatment with prednisone. (32) However, it is unclear whether the study had been confounded by the enrollment of patients with low disease activity and/or the concomitant use of corticosteroids in each treatment group. In patients with rheumatoid arthritis, there is more experience and published literature available about the efficacy and safety of MTX -anti-TNF combination therapy. (33) (34) (35) The authors of a recently published meta-analysis suggest that the combination of MTX and anti-TNF therapy better reduce disease activity and obtain remission than anti-TNF monotherapy. (36) With the increased use of anti-TNF treatment in IBD, it seems very justifiable to further explore the potential role of the MTX combination therapy, not only in CD patients, but also in UC patients.
PART II -OPTIMIZING THE ACCURACY AND PRACTICALITY OF CALPROTECTIN MEASUREMENTS IN DISEASE MONITORING
FC is increasingly used for monitoring response to treatment or early recognition of flares in patients with IBD. Many clinicians allow patients to send a stool sample to the laboratory by surface mail at ambient temperatures. (37, 38) Since the stability of the calprotectin protein at room temperature has remained rather unclear, we performed a FC stability study (chapter 5). We observed that stool calprotectin at room temperature is rather unstable, with a steady decline in calprotectin concentration in the first 6 days after stool collection. In clinical practice this does not mean that all FC test results from sent-in stool samples underestimate the actual disease activity, but this discovery does 205 9 warn us that when the FC result is in the uncertain range (250 -500 µg/g) we should be more careful with our interpretation. Although data indicate that FC is currently the best marker available (chapter 1), it is certainly not the ideal marker. One of the reasons why FC is not ideal is that there is no linear relationship between the extent and severity of the disease and the level of FC. This is why we advise to use a two-threshold strategy when interpreting FC for monitoring disease activity (see figure 1 ). Based on previous literature, FC values above 500 µg/g best correspond with active disease and is therefore chosen as the upper threshold. (59) (60) (61) In the action range (red zone), adjusting the treatment is advised to attempt to get the patient back into remission again. Despite the fact there is no consensus on the upper limit of the FC target range for remission (green zone), we use a value of 250 µg/g since multiple studies have shown that FC values below 250 µg/g correspond well with disease in remission. (13, 46, 56, (61) (62) (63) (64) The ideal biomarker should be easily accessible, non-invasive, low in costs and reflect the degree of tissue damage and repair. Table 1 . provides an overview of possible other biomarkers that can be found in different biological specimens including, blood, faeces, urine and saliva. Other blood inflammatory markers that have been suggested, include the non-protein amino acid citrullin, which is synthesized by the enterocytes of the small intestine and the intestinal fatty acid binding protein (I-FABP), which is an endogenous cytosolic enterocyte protein released by dying mature enterocytes and therefore a possible marker of enterocyte loss in the small intestine. (65) (66) (67) (68) The downside of using blood markers is the required invasiveness to obtain the sample. Non-invasive biomarkers like FC are certainly less invasive, although sampling feces may not be considered convenient by patients. Different faecal markers have been evaluated, but only FC and lactoferrin are used in clinical practice. This is because most other faecal biomarkers that have been investigated, like calgranulin C and polymorphonuclear neutrophil elastase (PMN-e), deal with the same advantages and disadvantages as faecal calprotectin, since they also are neutrophil-derived proteins. (69, 70) While a faecal biomarker may seem to be the obvious choice in an intestinal disease, we should not overlook the usefulness of other non-invasive biomarkers. Perhaps the measurement of Figure 1 . The two-threshold strategy with three calprotectin ranges. (i.e., <250 µg/g for target range, 250-500 µg/g for uncertain range, and >500 µg/g for active disease) 207 9 urinary claudin-3, which is a protein that indicates tight junction breakdown that is an early event in the development of intestinal damage, can be used in IBD patients. (71) or the measurement of cytokines like IL-1ẞ, IL-6 and TNF-а in the saliva. (72, 73) In the meantime, FC remains the best known and most studied biomarker of inflammation currently available in IBD.(37,62,74-76) Our present data indicate that stool calprotectin is not stable at room temperature (chapter 5 and 6). Although we only tested a limited amount of samples, our message got picked up incredibly fast, expressing the urgent need for more literature on this topic. Within half a year not only the FC handling instruction in our own hospital has been adapted, but the issue is now also being addressed in the national paediatric IBD treatment guidelines. (77) This finding could be seen as a setback for the previously cherished practicallity of the FC test, however manufacturers have now realized that there is considerable profit in further improving the lateral flow-based technique to measure calprotectin with a smartphone at home. (78) (79) (80) (81) The home tests have now been investigated under ideal circumstances in the hospital laboratory as well as by the patients themselfes at home, but only in a research setting, not as part of regular care. The next step will involve incorporating the FC home test in routine clinical practice, to determine whether patients who use this telemonitoring possiblity fare better than those who do not. Furthermore, future studies will focus on connecting each FC home test result, in a series of repeated FC measurements during follow-up, immediately to an automatically generated treatment advise. This advise is based on the possible rise of calprotectin out of the target range in the early stage of an upcoming relapse what could allow the assess of early intervention. The future will tell us whether preemptive treatment optimization is a feasible strategy, resulting in a decrease of the number of relapses and prevention of progressive bowel damage in the long-term, both in adults as well as in children.
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Potential biomarkers What it measures
Blood ■ Citrullin (67, 82) ■ Intestinal fatty acid binding protein (I-FABP) (65, 66, 83) Urine ■ Claudin-3 (71) Saliva ■ Cytokines □ In CD patients: IL-1ẞ, IL-6
and TNF-а (72) □ In UC patients: TGF-ẞ1 and NO (73) Faeces ■ Calgranulin C (84) (85) (86) ■ Polymorphonuclear neutrophil elastase (PMN-e) (40, 87) ■ Human neutrophil peptides (HNPs) (88) ■ Neutrophil gelatinaseassociated lipocalin (NGAL) (89, 90) ■ Matrix metalloproteinase 9
(MMP9) (91, 92) ■ Myeloperoxidase (MPO) (93, 94) ■ High-mobility group box 1 (HMGB1) (95) ■ Neopterin (96, 97) PSC is a relatively rare (8-10%), but serious complication of IBD. It is suggested that childhood-onset PSC presents with milder disease and has a more favourable outcome compared to adultonset PSC. To compare outcomes between paediatric-and adult onset PSC we evaluated time-to-complication curves in two independent Dutch PSC cohorts (chapter 7). We found that a quarter of the childhood-onset PSC patients developed biliary and portal hypertensive complications or progressed to liver transplantation in the first five years postdiagnosis. Furthermore, we showed that paediatric-and adult-onset PSC run a similar progressive disease course with no differences seen between both cohorts with regard to frequencies of liver transplantations or the mean disease duration until liver transplantation. Our findings suggest that both the paediatricians as well as the adult-oriented specialists need to be aware of serious complications that might accompany childhood-onset PSC possibly already early during the course of disease.
In analogy with recently published family-based studies on monogenic forms of other complex (auto-)immune diseases (98) (99) (100) , we hypothesized that in a fraction of patients with earlyonset PSC, the disease is caused by rare genetic variants as well. In chapter 8 we therefore performed a family-based study, in which we examined the DNA of patients with early-onset PSC and their biological parents. Whole exome sequencing (WES) of all protein-coding genes results in many variants of uncertain clinical significance. A trio-analysis design, i.e. the inclusion of patients and parents in the analysis of rare genetic variants, helped to immediately ascertain whether a variant is inherited or has arisen de novo, i.e. as a new mutation in the child during foetal development. This appeared to be a successful approach that revealed multiple candidate disease-causing variants with possibly large effects on protein function in several genes. Our findings suggest that PSC can also present in a rare, monogenic or oligogenic fashion, but this suggestion would be supported if functional experiments provide mechanistic insights in how this could possibly increase the risk of PSC.
PART III -PROFILING PATIENTS WITH CHILDHOOD-ONSET PRIMARY SCLEROSING CHOLANGITIS
Clinical Implications For years there have hardly been any studies focusing on the paediatric PSC populations. Accordingly, paediatricians had almost completely to relie on information available from adult PSC registries. (101) (102) (103) (104) (105) Recently the topic has gained interest, and new studies of paediatric PSC cohorts are being published. (106) (107) (108) (109) (110) However, most of the currently available studies are retrospective, single-centre designs and the rarity of the disease hampers the studies on providing information about clinical course and prognosis. Different perspectives exist concerning childhoodonset PSC and the long-term consequences. It has been assumed that children with PSC generally have an earlier stage of the same disease as adult PSC patients, tend to present with milder disease, and finally, have more favourable outcomes. (107, 108) However, there are also doubts about these assumptions since there are remarkable differences between adult-onset and childhood-onset disease, including higher incidence of the autoimmune-overlap syndrome and higher incidence of concomitant IBD in the latter. (111, 112) These differences may indicate that childhood-onset PSC is not merely an early stage of the same disease, but might rather involve a (partially) different immune-mediating pathophysiology. (113) Based on the findings shown in chapter 7, we argue that childhood-onset PSC follows at least the same progressive disease course as adult-onset disease. We can not even exclude that nearly all childhood-onset patients will need a liver transplantation at some point during their lives, although current registries do not have a sufficiently long time follow up to test this hypothesis. The prognostic factors we identified now in combination with those identified in previous studies, can be used to target and select those patients with a high risk of early hepatic deterioration. Eventhough the therapeutic options to modify the disease course are presently very limited, prognostic factors can be used for early recognition and prevention of complications, selecting patients for clinical trials, and promote timely listing for liver transplantation.
The aetiology of PSC will hopefully become more clear in the upcoming years. Important developments will occur in the field of genetics and immunology. Genome-wide association studies (GWAS) have identified a large number of disease susceptibility genes, showing a strong overlap with the genetic architecture of IBD and other autoimmune diseases in general. (114) (115) (116) (117) (118) (119) (120) (121) The 211 9 expectations were high that these risk genes would quickly lead to new drug targets for PSC, but so far this is not the case. How to convert the increasing list of genetic risk loci into tailored management for the individual patient, remains unclear. (122) Furthermore the contribution of these already identified risk genes to overall PSC burden is only about 5%. (120, 123) Actual cure requires insight into causation of the disease. In chapter 8 we have shown a method to identify candidate disease causing genes in early-onset PSC patients and concluded that there may be monogenic or oligogenic forms of PSC as well. The family-based strategy permitted efficient discovery of de novo mutations and compound heterozygous genotypes in our cohort. Furthermore, we used multiple pathogenicity tools to predict if our variants are deleterious based on whether the site of the variant displays evolutionary conservation (124) , or is predicted to be damaging according to known gene function. We do recognize that this is not sufficient to implicate a variant as playing a causal role in disease, since even healthy individuals carry many rare protein-disrupting variants. (125, 126) Assessment of evidence for variant implication in a certain disease is challenging and requires a step-wise approach (see Tabel 2), as suggested by a working group of experts in genomic research, analysis and clinical diagnostic sequencing convened by the US National Human Genome Research Institute. (126) For our WHELPstudy, the next step will involve experimental validation of our findings to determine a poptential pathophysiologoical impact of one or more of our candidate variants. If we can demonstrate that a gene product is functionally disrupted by one (or more) of the present candidate mutations, this discovery may serve as an important clue that could lead to understanding of the individual underlying pathogenic mechanism. Although monogenic or oligogenic variants may only explain disease-onset in a small proportion of the total PSC population, understanding how the loss of the involved protein functions results in the monogenic PSC-like phenotype can also be very informative for complex PSC. Uncovering genetic variants that provide causal evidence will provide valuable insights in terms of both biological understanding, but most important, it might help to take our main goal, to design new targeted therapies and personalize the medicine, to the next level.
Genetic evidence
1. Determine and report the formal statistical evidence for segregation or association of each variant, and its frequency in large control populations matched as closely as possible to patients in terms of ancestry.
Informative evidence
Predict variant deleteriousness based on evolutionary conservation;
■ the site of the variant displays evolutionary conservation consistent with deleterious effects of sequence changes at that location, and/or; Predict that a variant is damaging in terms of biological function; ■ the variant is found at the location within the protein predicted to cause functional disruption (for example, enzyme active site, protein-binding region).
Experimental evidence
3. Validate experimentally the predicted damaging impact of candidate variants using assays of patient-derived tissue or wellestablished cell or animal models of gene function. 4 . Avoid assuming that implicated variants are fully penetrant, or completely explanatory in any specific disease case. 
CONCLUSION
In this thesis we aimed to contribute to the further development of personalized medicine in paediatric IBD. Most of the studies that have been published so far, including our present work, use prognostic factors to identify subgroups of patients and are not tailored to the individual patient. Personalized medicine in the way we conducted it now may therefore better be called 'stratified medicine'. Our results of the WHELP-study might give a glimpse of what we can expect in the near future. Knowledge of the underlying pathogenic mechanisms in each individual patient at diagnosis may allow early adaptation of therapeutic pathways with the aim to enhance treatment efficacy while minimizing or even avoiding drug-toxicity complications. Advances in molecularmedicine will allow more precise drug targeting. Based on the current developments, I expect that IBD care will gradually move from "stratified medicine" via "personalized medicine" towards "precision medicine". 9 Gastroenterol Nutr 2009 May 01;48 (5) 
